Gilead Sciences (GILD) says the FDA has approved StribildT, a complete once-daily single tablet...

|About: Gilead Sciences, Inc. (GILD)|By:, SA News Editor

Gilead Sciences (GILD) says the FDA has approved StribildT, a complete once-daily single tablet regimen for HIV-1 infection for treatment-naive adults. The drug - once referred to as the "Quad" prior to FDA approval - is a co-formulated HIV medicine that simplifies therapy by combining four compounds into one daily tablet. Shares +0.7% AH.